Imigliptin

Drug Profile

Imigliptin

Alternative Names: 3853; Imigliptin dihydrochloride - Sihuan; KBP 3853

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group
  • Class Antihyperglycaemics; Imidazoles; Nitriles; Piperidines; Pyridines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 04 Aug 2016 China FDA approves phase II/III trials of imigliptin in Type-2 diabetes mellitus
  • 04 Aug 2016 XuanZhu Pharma plans a phase II/III trial for Type-2 diabetes mellitus in China
  • 18 Oct 2013 Phase-I clinical trials in Type-2 diabetes mellitus in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top